Dimethyltryptamine

DRAPER, Utah, May 27, 2026 /PRNewswire/ -- The FDA recently announced it is shifting regulatory attention and investment for emerging psychedelic-based therapeutics treating mental health conditions. CenExel Clinical Research is answering this push with expansion to support psychedelic clinical trials targeting conditions including depression, PTSD, anxiety, addiction, and other neuropsychiatric disorders. As interest in psychedelic therapies accelerates across the pharmaceutical and biotechnology industries, sponsors and CROs are increasingly looking for experienced clinical research partners capable of managing the specialized operational and patient care demands that these studies require. Through its nationwide network of Centers of Excellence, CenExel has continued to invest in the infrastructure, training, operational processes, and experienced staff needed to support complex psychedelic clinical research. "Psychedelic therapies represent one of the most promising emerging areas in investigational treatments for population mental health," said Alex Kelman, PhD, Psychedelic Facilitator for CenExel. "Given the substantial unmet need across so many mental health conditions, bringing rigorous scientific attention to these approaches is a genuine public health priority." Sponsors already look to CenExel as an experienced clinical research partner who can manage the unique operational, scientific, and patient-care requirements associated with these studies as sites across its network are already equipped with the dedicated infrastructure, staff and experienced principal investigators. Several CenExel locations feature purpose-built psychedelic treatment environments designed to support pre-dose sessions, post-dose sessions, extended dosing sessions, patient comfort, safety monitoring, and sponsor oversight. One CenExel site alone has conducted more than 400 cumulative Schedule I dosing sessions involving compounds like LSD, 5-MeO-DMT, psilocybin, psilocin, and DMT, demonstrating active, real world operational experience supporting these highly specialized studies. CenExel's capabilities supporting psychedelic clinical trials include: Extensive experience conducting complex CNS and behavioral health studies Access to specialized patient populations across multiple indications Highly trained investigators and site staff experienced in neuropsychiatric research Dedicated treatment rooms equipped with AV designed to execute and monitor complex trials during psychedelic dosing visits Centralized recruitment, patient retention, and operational support services Nationwide scalability through CenExel's network of research sites Inspection ready operational models supporting both early and late phase psychedelic programs Psychedelic clinical trials require a differentiated approach compared to traditional pharmaceutical studies. CenExel's operational framework is designed to help sponsors navigate these complexities while maintaining accurate data collection and patient care. CenExel's operational metrics and capabilities reinforce a clear message that they are actively conducting psychedelic research at scale today, while continuing to evaluate how to expand services to support these complex studies. "As interest from regulators, sponsors, clinicians, and patients continues to increase, it's critical that clinical trials are conducted with scientific rigor, operational excellence, and a strong focus on patient safety and experience," said Kelman. "CenExel has built the therapeutic expertise, site capabilities, and patient engagement infrastructure needed to help advance this important area of research." About CenExel CenExel is a leading, wholly owned clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies. CenExel provides unparalleled research support in the design and execution of complex clinical trials, leveraging scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence. Located across multiple major metro areas, CenExel's Centers of Excellence sites have conducted thousands of studies with precision, accuracy, and speed. The company's unwavering commitment to quality, the patient experience, and client success ensures successful clinical development outcomes. CenExel's expertise and execution capabilities help pharmaceutical and biotech companies gain deeper insights into diseases, accelerating clinical development to deliver innovative treatments and improve global patient outcomes. To learn more visit Media Contact: George Protopapadakis Public Relations Consultant [email protected] 786.200.7918 SOURCE CenExel Clinical Research 21% more press release views with Request a Demo

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 25, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has amended the warrant terms of its recently announced non-brokered private placement, removing the acceleration feature and extending the warrant exercise period to 3 years. All other terms remain unchanged. Summary of Amended Offering Terms The Company recently announced a non-brokered private placement for gross proceeds of CAD $1,000,000 of units at an issue price of CAD $0.40 per Unit. Each Unit will consist of one Class A common share in the capital of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to acquire one Common Share (a “Warrant Share”) at an exercise price of CAD $0.60 (the “Exercise Price”) per Warrant Share for a period of 36 months from the issuance date (the “Expiry Date”). The Company will use the proceeds of the Offering to advance its Alzheimer’s Disease program towards the opening of its first U.S. brain-specific neuroimaging clinic, general and administrative expenses, and for working capital purposes. The securities issued and issuable, described in this news release, will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable Canadian securities legislation. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration. Christopher J. Moreau CEO Grey Matters Health Inc. 604.398.4175 Ext 701 cjmoreau@greymatters-health.com info@greymatters-health.com www.greymatters-health.com About Grey Matters Grey Matters is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease, and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson’s disease. Grey Matters has a program for Repirinast, a repurposed drug for CKD, and is also the parent company of Algernon NeuroScience, a wholly owned subsidiary, that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury recovery. The Company’s chronic cough drug Ifenprodil, which works by stopping cough in the brain, was sold for USD $2M cash and a 20% equity position in Seyltx, a private U.S. based drug development company that continues to advance research on the drug. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.